Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Markets Sluggishly Move to Year-End

MT NewswiresDec 27 08:06 ET

BeiGene Gains FDA Nod for TEVIMBRA, Marking Key Progress in Oncology Treatments

BenzingaDec 27 06:01 ET

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemotherapy

BusinesswireDec 27 06:00 ET

Express News | Tevimbra Approved in U.S. for First-Line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemotherapy

ReutersDec 27 06:00 ET

Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.

The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.

Zhitong FinanceDec 25 21:48 ET

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24 04:16 ET